Table 1.
Demographics of integrated data from 3 indications: renal cell carcinoma (RCC), hepatocellular carcinoma (HCC) and differentiated thyroid carcinoma (DTC)
| Variables | Before propensity score matching | After propensity score matching | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| eGFR (mL/min/1.73 m2) | p-value | eGFR (mL/min/1.73 m2) | p-value | |||||||
| < 60 (N = 2482) | ≥ 60 (N = 2219) | < 60 (N = 1215) | ≥ 60 (N = 1215) | |||||||
| Gender, n (%) | ||||||||||
| Male | 1857 (74.8) | 1628 (73.4) | 0.2563 | 894 (73.6) | 897 (73.8) | 0.8901 | ||||
| Female | 625 (25.2) | 591 (26.6) | 321 (26.4) | 318 (26.2) | ||||||
| Age (y), mean ± SD | 68.4 ± 9.4 | 64.7 ± 10.7 | < 0.0001 | 66.9 ± 10.1 | 66.6 ± 10.3 | 0.5930 | ||||
| Weight (kg), mean ± SD | 59.15 ± 11.17 | 58.98 ± 12.07 | 0.6308 | 59.14 ± 11.64 | 58.69 ± 11.96 | 0.3496 | ||||
| BMI (kg/m2), mean ± SD | 22.61 ± 3.36 | 22.45 ± 3.77 | 0.1500 | 22.54 ± 3.50 | 22.43 ± 3.77 | 0.4695 | ||||
| ECOG Performance Status*, n (%) | ||||||||||
| 0 | 1620 (65.3) | 1384 (62.4) | < 0.0001 | 778 (64.0) | 772 (63.5) | 0.9191 | ||||
| 1 | 768 (30.9) | 690 (31.1) | 382 (31.4) | 384 (31.6) | ||||||
| ≥ 2 | 93 (3.8) | 145 (6.5) | 55 (4.5) | 59 (4.9) | ||||||
| Baseline eGFR (mL/min/1.73 m2), mean ± SD | 44.15 ± 12.25 | 80.75 ± 25.64 | < 0.0001 | 45.57 ± 11.96 | 77.46 ± 17.23 | < 0.0001 | ||||
| TNM stage, n (%) | ||||||||||
| I/II/III | 197 (7.9) | 336 (15.1) | < 0.0001 | 145 (11.9) | 161 (13.3) | 0.1034 | ||||
| IVA | 2042 (82.3) | 1266 (57.1) | 877 (72.2) | 819 (67.4) | ||||||
| IVB | 169 (6.8) | 458 (20.6) | 143 (11.8) | 167 (13.7) | ||||||
| IVC | 21 (0.9) | 63 (2.8) | 16 (1.3) | 22 (1.8) | ||||||
| Unknown | 53 (2.1) | 96 (4.3) | 34 (2.8) | 46 (3.8) | ||||||
| Prior surgery, n (%) | 2202 (88.7) | 1834 (82.7) | < 0.0001 | 1076 (88.6) | 991 (81.6) | < 0.0001 | ||||
| Prior systemic anticancer therapy*, n (%) | 1656 (66.7) | 922 (41.6) | < 0.0001 | 671 (55.2) | 634 (52.2) | 0.1322 | ||||
| Metastases, n (%) | ||||||||||
| Any site* | 2095 (84.4) | 1501 (67.6) | < 0.0001 | 927 (76.3) | 890 (73.3) | 0.0840 | ||||
| Bone | 604 (24.3) | 541 (24.4) | 0.9713 | 290 (23.9) | 324 (26.7) | 0.1125 | ||||
| Brain | 93 (3.8) | 72 (3.2) | 0.3502 | 42 (3.5) | 52 (4.3) | 0.2928 | ||||
| Lung | 1476 (59.5) | 962 (43.4) | < 0.0001 | 623 (51.3) | 604 (49.7) | 0.4408 | ||||
| Comorbidity, n (%) | ||||||||||
| Cardiac* | 942 (38.0) | 462 (20.8) | < 0.0001 | 360 (29.6) | 316 (26.0) | 0.0464 | ||||
| Pulmonary | 98 (4.0) | 86 (3.9) | 0.8977 | 50 (4.1) | 45 (3.7) | 0.6008 | ||||
| Renal | 257 (10.4) | 29 (1.3) | < 0.0001 | 130 (10.7) | 13 (1.1) | < 0.0001 | ||||
| Baseline AST (IU/L), mean ± SD | 32.89 ± 41.88 | 48.38 ± 56.76 | < 0.0001 | 40.30 ± 54.43 | 39.45 ± 46.20 | 0.6770 | ||||
| Baseline ALT (IU/L), mean ± SD | 25.40 ± 33.24 | 34.08 ± 31.19 | < 0.0001 | 29.62 ± 42.20 | 29.42 ± 29.42 | 0.8922 | ||||
| Total bilirubin (mg/dL), mean ± SD | 0.65 ± 0.53 | 0.84 ± 0.87 | < 0.0001 | 0.71 ± 0.58 | 0.73 ± 0.53 | 0.3797 | ||||
| Baseline albumin (g/dL), mean ± SD | 3.69 ± 0.97 | 3.49 ± 0.64 | < 0.0001 | 3.64 ± 1.19 | 3.54 ± 0.65 | 0.0145 | ||||
| Baseline creatinine (mg/dL), mean ± SD | 1.48 ± 1.38 | 0.73 ± 0.15 | < 0.0001 | 1.41 ± 1.29 | 0.75 ± 0.15 | < 0.0001 | ||||
| BMI ≥ 25 kg/m2, n (%) | 459 (18.5) | 418 (18.8) | 0.7623 | 252 (20.7) | 248 (20.4) | 0.8409 | ||||
| Observation days, median (IQR) | 245.0 (298.0) | 195.0 (291.0) | < 0.0001 | 207.0 (301.0) | 217.0 (287.0) | 0.4389 | ||||
| Initial sorafenib dose*, n (%) | ||||||||||
| 800 mg | 1880 (75.8) | 1666 (75.1) | 0.5962 | 923 (76.0) | 936 (77.0) | 0.5339 | ||||
| < 800 mg | 602 (24.3) | 553 (24.9) | 292 (24.0) | 279 (23.0) | ||||||
| Weight by sex*, n (%) | ||||||||||
| < Median | 1077 (48.5) | 1025 (50.6) | 0.1720 | 609 (50.1) | 618 (50.9) | 0.7150 | ||||
| ≥ Median | 1145 (51.5) | 1002 (49.4) | 606 (49.9) | 597 (49.1) | ||||||
| Baseline AST*, n (%) | ||||||||||
| < Median | 1277 (51.9) | 1064 (48.1) | 0.0105 | 603 (49.6) | 616 (50.7) | 0.5979 | ||||
| ≥ Median | 1186 (48.2) | 1148 (51.9) | 612 (50.4) | 599 (49.3) | ||||||
| Baseline ALT*, n (%) | ||||||||||
| < Median | 1330 (54.1) | 999 (45.1) | < 0.0001 | 632 (52.0) | 603 (49.6) | 0.2393 | ||||
| ≥ Median | 1130 (45.9) | 1215 (54.9) | 583 (48.0) | 612 (50.4) | ||||||
| Baseline platelet count*, n (%) | ||||||||||
| < Median | 1326 (53.7) | 975 (44.2) | < 0.0001 | 575 (47.3) | 549 (45.2) | 0.2901 | ||||
| ≥ Median | 1145 (46.3) | 1232 (55.8) | 640 (52.7) | 666 (54.8) | ||||||
| Baseline haemoglobin*, n (%) | ||||||||||
| < Median | 1272 (51.5) | 1040 (47.1) | 0.0030 | 617 (50.8) | 612 (50.4) | 0.8392 | ||||
| ≥ Median | 1198 (48.5) | 1166 (52.9) | 598 (49.2) | 603 (49.6) | ||||||
| Time from diagnosis (d)*, n (%) | ||||||||||
| < median | 61 (49.2) | 124 (50.6) | 0.7968 | 42 (49.4) | 52 (53.6) | 0.5719 | ||||
| ≥ median | 63 (50.8) | 121 (49.4) | 43 (50.6) | 45 (46.4) | ||||||
| Application at initial dose*, n (%) | 283 (11.4) | 425 (19.2) | < 0.0001 | 179 (14.7) | 199 (16.4) | 0.2630 | ||||
| Hypertension medicine at initial dose*, n (%) | 372 (15.0) | 432 (19.5) | < 0.0001 | 229 (18.9) | 245 (20.2) | 0.4127 | ||||
| Distribution of indications, n (%) | ||||||||||
| Renal cell carcinoma | 1930 (77.8) | 933 (42.1) | < 0.0001 | 761 (62.6) | 691 (56.9) | 0.0150 | ||||
| Hepatocellular carcinoma | 423 (17.0) | 1023 (46.1) | 365 (30.0) | 420 (34.6) | ||||||
| Differentiated thyroid carcinoma | 129 (5.2) | 263 (11.9) | 89 (7.3) | 104 (8.6) | ||||||
ALT alanine aminotransferase, AST aspartate aminotransferase, BMI body mass index, ECOG PS Eastern Cooperative Oncology Group performance status, eGFR estimated glomerular filtration rate, IQR interquartile range, TNM tumor, node, metastasis
*Indicates variable used for propensity score matching